Dr. Reddy’s Laboratories Limited (RDY)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s Laboratories” or “the Company”) (NYSE: RDY). Investors who purchased Dr. Reddy’s Laboratories securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Dr. Reddy’s Laboratories has violated federal securities laws.
Dr. Reddy’s Laboratories Investigation Details
On July 22, 2026, Dr. Reddy’s Laboratories reported first-quarter fiscal 2027 financial results that missed expectations and disclosed a ₹2.4 billion provision related to out-of-specification semaglutide batches. During the accompanying earnings call, Chief Executive Officer Erez Israeli stated that there was “no impact on the product’s existing global regulatory filings” and “no patient-safety impact associated with product already supplied to the market.” This disclosure followed the Company’s earlier statements highlighting semaglutide approvals and product launches, including Obeda in Canada and the approval of oral semaglutide in India. Following this news, Dr. Reddy’s Laboratories’ stock price fell approximately 9%.
What’s Next for Dr. Reddy’s Laboratories Investors?
If you are aware of any facts relating to this investigation or purchased Dr. Reddy’s Laboratories securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to Dr. Reddy’s Laboratories Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC For Dr. Reddy’s Laboratories Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,” said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.